DK0633886T3 - Farmaceutisk aktive bicyclisk-heterocycliske aminer - Google Patents

Farmaceutisk aktive bicyclisk-heterocycliske aminer

Info

Publication number
DK0633886T3
DK0633886T3 DK93908303T DK93908303T DK0633886T3 DK 0633886 T3 DK0633886 T3 DK 0633886T3 DK 93908303 T DK93908303 T DK 93908303T DK 93908303 T DK93908303 T DK 93908303T DK 0633886 T3 DK0633886 T3 DK 0633886T3
Authority
DK
Denmark
Prior art keywords
pharmaceutically active
heterocyclic amines
active bicyclic
bicyclic
xxx
Prior art date
Application number
DK93908303T
Other languages
Danish (da)
English (en)
Inventor
Gordon L Bundy
Eric Jon Jacobsen
Donald E Ayer
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0633886T3 publication Critical patent/DK0633886T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DK93908303T 1992-04-03 1993-03-16 Farmaceutisk aktive bicyclisk-heterocycliske aminer DK0633886T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86364692A 1992-04-03 1992-04-03
PCT/US1993/002188 WO1993020078A1 (en) 1992-04-03 1993-03-16 Pharmaceutically active bicyclic-heterocyclic amines

Publications (1)

Publication Number Publication Date
DK0633886T3 true DK0633886T3 (da) 2000-12-18

Family

ID=25341481

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93908303T DK0633886T3 (da) 1992-04-03 1993-03-16 Farmaceutisk aktive bicyclisk-heterocycliske aminer

Country Status (21)

Country Link
EP (1) EP0633886B1 (de)
JP (1) JPH08502721A (de)
KR (1) KR100284473B1 (de)
AT (1) ATE197051T1 (de)
AU (1) AU675932B2 (de)
CA (1) CA2130937A1 (de)
CZ (1) CZ236494A3 (de)
DE (1) DE69329574T2 (de)
DK (1) DK0633886T3 (de)
ES (1) ES2150941T3 (de)
FI (1) FI944602A0 (de)
GR (1) GR3035188T3 (de)
HU (1) HUT70954A (de)
LV (1) LV12794B (de)
MX (1) MX9301847A (de)
NO (1) NO303542B1 (de)
PL (2) PL175327B1 (de)
PT (1) PT633886E (de)
RU (1) RU2103272C1 (de)
SK (1) SK119194A3 (de)
WO (1) WO1993020078A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795986A (en) * 1995-03-02 1998-08-18 Pharmacia & Upjohn Company Pyrimido 4,5-B!indoles
US5753635A (en) * 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
WO1998024453A1 (en) * 1996-12-05 1998-06-11 Nippon Shinyaku Co., Ltd. Remedies for myelopathy
NZ336659A (en) * 1997-01-08 2001-01-26 Upjohn Co Pharmaceutically active pyrimido[4,5-b]indoles
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
YU76100A (sh) 1998-06-02 2003-12-31 Osi Pharmaceuticals Inc. Pirolo(2,3-d) pirimidin preparati i njihova primena
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2003524598A (ja) * 1998-09-04 2003-08-19 アルタナ ファルマ アクチエンゲゼルシャフト 新規ピラノセン
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
KR100840727B1 (ko) * 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
WO2002004447A1 (en) * 2000-07-11 2002-01-17 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
SE0003795D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
CN101973998A (zh) 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1615930A2 (de) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Als a2a-adenosinrezeptor-antagonisten geeignete triazolotriazine und pyrazolotriazine
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070185217A1 (en) 2003-12-23 2007-08-09 Abraxis Bioscience, Inc. Propofol analogs, process for their preparation, and methods of use
EP1724277A4 (de) * 2004-03-04 2012-05-02 Kissei Pharmaceutical Derivat mit kondensiertem heterocyclus, medizinische zusammensetzung, die dieses enthält, und deren medizinische verwendung
RU2007101544A (ru) 2004-06-17 2008-08-10 Уайт (Us) Антагонисты рецепторов высвобождающего гонадотропин гормона
RU2007101509A (ru) 2004-06-17 2008-07-27 Уайт (Us) Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин
MXPA06014535A (es) 2004-06-18 2007-06-05 Biolipox Ab Indoles utiles en el tratamiento de la inflamacion.
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
BRPI0519774A2 (pt) 2005-01-19 2009-02-10 Biolipox Ab composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
FR2884824B1 (fr) 2005-04-20 2007-07-13 Sanofi Aventis Sa Derives de 1h-pyrimido[4,5-b]indole, leur preparation et leur application en therapeutique
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
KR100749216B1 (ko) * 2006-08-30 2007-08-13 위아 주식회사 4륜구동차량용 부변속기
WO2008055808A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
US7981903B2 (en) * 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
CN101801965B (zh) * 2007-08-17 2014-07-30 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚化合物
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
MX2010007661A (es) 2008-01-31 2010-08-03 Sanofi Aventis Azaindol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos.
TW200938201A (en) * 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
US8586582B2 (en) 2008-11-11 2013-11-19 Xcovery Holding Company, Llc PI3K/mTOR kinase inhibitors
JP5719028B2 (ja) 2010-10-06 2015-05-13 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体
JP5963777B2 (ja) 2011-01-31 2016-08-03 ノバルティス アーゲー 新規ヘテロ環誘導体
US9732083B2 (en) 2011-03-15 2017-08-15 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
PT2807165T (pt) 2012-01-27 2019-07-12 Univ Montreal Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas
WO2014001973A1 (en) 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
JP2017510628A (ja) 2014-03-13 2017-04-13 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 縮合ピリミジン系ヒドロキサメート誘導体
WO2016048861A2 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Heterocyclic compounds and use thereof
EP3303570B1 (de) 2015-06-05 2021-01-20 Héma-Québec Verfahren zur kultivierung und/oder differenzierung hämatopoetischer stammzellen in vorläufer und verwendungen davon
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019158731A1 (en) * 2018-02-16 2019-08-22 Ucb Biopharma Sprl Pharmaceutical 6,5 heterobicyclic ring derivatives
EP3906026A4 (de) * 2018-12-31 2022-10-19 Biomea Fusion, LLC Irreversible inhibitoren der menin-mll-interaktion
EP4161519A4 (de) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. Purine und verfahren zu ihrer verwendung
WO2021263079A1 (en) * 2020-06-26 2021-12-30 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
EP0514540B1 (de) * 1989-09-19 1996-07-17 Teijin Limited Pyrrolo[2,3-d]pyrimidinderivate, verfahren zur herstellung und arzneimittelzusammensetzungen die diese enthalten

Also Published As

Publication number Publication date
FI944602L (fi) 1994-10-03
KR950700912A (ko) 1995-02-20
RU2103272C1 (ru) 1998-01-27
NO943655L (no) 1994-12-05
PL175347B1 (pl) 1998-12-31
LV12794A (en) 2002-02-20
ES2150941T3 (es) 2000-12-16
GR3035188T3 (en) 2001-04-30
NO943655D0 (no) 1994-09-30
MX9301847A (es) 1993-10-01
DE69329574T2 (de) 2001-05-31
FI944602A7 (fi) 1994-10-03
ATE197051T1 (de) 2000-11-15
HU9402829D0 (en) 1995-02-28
RU94042466A (ru) 1996-07-20
PT633886E (pt) 2001-03-30
FI944602A0 (fi) 1994-10-03
LV12794B (lv) 2002-06-20
AU675932B2 (en) 1997-02-27
SK119194A3 (en) 1995-05-10
CA2130937A1 (en) 1993-10-14
AU3917493A (en) 1993-11-08
CZ236494A3 (en) 1994-12-15
NO303542B1 (no) 1998-07-27
DE69329574D1 (de) 2000-11-23
PL175327B1 (pl) 1998-12-31
HUT70954A (en) 1995-11-28
JPH08502721A (ja) 1996-03-26
KR100284473B1 (ko) 2001-04-02
EP0633886B1 (de) 2000-10-18
WO1993020078A1 (en) 1993-10-14
EP0633886A1 (de) 1995-01-18

Similar Documents

Publication Publication Date Title
DK0633886T3 (da) Farmaceutisk aktive bicyclisk-heterocycliske aminer
TR199900204T2 (xx) Fluor i�eren 1,4-diikameli piperidin t�revleri.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
NO20025450D0 (no) Ny farmasöytisk sammensetning
BR9806157A (pt) Composições farmacêuticas de descarboetoxiloratadina anidras, não higroscópicas e sem lactose
PT705100E (pt) Guanidinas substituidas terapeuticas
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
BR9903737A (pt) Carbamatos em c-11 de macrólidos antibacterianos
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
SE9900833D0 (sv) Novel combination
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
BR0115883A (pt) Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
SE9900834D0 (sv) Novel combination
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
MY130725A (en) Composition and method for treating allergic diseases
CA2404210A1 (en) Pharmaceutical gel composition
PT882038E (pt) N-metil-n-(4-(piperidin-1-il)-2-(aril)butil)benzamidas substituidas vantajosas para o tratamento de doencas alergicas
FI965114A7 (fi) Farmaseuttinen koostumus virusinfektioiden sekä valinnaisesti tulehdusten estoon ja (tai) hoitoon sekä niiden hoitomenetelmä
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
DE69731620D1 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten